Author

R. Namdari

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 1 Organism:plant (other)· 1 Organism:rat· 1

Frequent Co-Authors

A. J. Cutts· 2 shared C. Young· 2 shared L. Sojo· 2 shared M. Grimwood· 2 shared M. Waldbrook· 2 shared S. Chowdhury· 2 shared S. Lin· 2 shared Z. Xie· 2 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. J. Cutts

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1 (DMT1): Preclinical Efficacy Against Iron Overload and Safety Evaluation

A. J. Cutts, S. Chowdhury, L. Ratkay, M. Eyers, C. Young, R. Namdari, J. Cadieux, N. Chahal, M. Grimwood, Z. Zhang, S. Lin, I. Tietjen, Z. Xie, L. Robinette, L. Sojo, , C. J. Cohen

This paper identifies XEN602, a potent, gut-restricted DMT1 inhibitor, showing efficacy in reducing iron overload in rats and pigs with minimal systemic exposure.

bioRxiv · Sep 1, 2022Pharmacology & Toxicology

NBI-921352, a First-in-Class, Na V 1.6 Selective, Sodium Channel Inhibitor That Prevents Seizures in Scn8a Gain-of- Function Mice, and Wild-Type Mice and Rats

J. Johnson, T. Focken, K. Khakh, P. K. Tari, C. Dube, A. Williams, J.-C. Andrez, G. Bankar, D. Bogucki, K. Burford, E. Chang, S. Chowdhury, R. Dean, G. de Boer, S. Decker, , W

This paper describes NBI-921352, a selective NaV1.6 inhibitor that prevents seizures in Scn8a gain-of-function mice and wild-type models, with better efficacy and tolerability than existing antiseizure drugs.

eLife · Mar 2, 2022Peer-reviewedPharmacology & Toxicology